华大智造(688114.SH)发布2025 年年度业绩预告，经初步测算，公司预计2025年年度实现归属于母公司 所有者的净利润为亏损2.21亿元到2.73亿元，与上年同期相比，亏损将减少3.28亿元到亏损减少3.80亿 元。报告期内，由于美元、欧元汇率波动，导致公司持有外币货币性项目产生的汇兑收益同比增加。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

证券代码：688114 证券简称：华大智造 公告编号：2026-001 深圳华大智造科技股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重点内容提示 ●公司经初步测算，深圳华大智造科技股份有限公司（以下简称"公司"）预 计2025年年度实现归属于母公司所有者的净利润与上年同期（法定披露数据）相比， 实现归属于母公司所有者的净利润-27,300.00万元到-22,100.00万元，与上年同期相 比，亏损将减少32,782.70万元到亏损减少37,982.70万元，同比亏损减少54.56%到亏 损减少63.22%。 ●公司预计 2025 年年度实现归属于母公司所有者的扣除非经常性损益的净利润 -39,700.00 万元到-32,200.00 万元，与上年同期相比，亏损将减少 25,570.68 万元到 亏损减少 33,070.68 万元，同比亏损减少 39.18%到亏损减少 50.67%。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告 ...

报告期内，公司制定了一系列"提质增效重回报"措施，包括人效提升、研发聚焦、营销费用全周期管理 等措施，导致公司相关的成本费用相比同期减少。报告期内，由于美元、欧元汇率波动，导致公司持有 外币货币性项目产生的汇兑收益同比增加。报告期内，上半年对以前年度涉及的不确定性的税务争议风 险相应的税务拨备进行冲回处理，导致所得税费用同比减少。根据企业会计准则及公司会计政策等相关 规定，基于谨慎性原则，公司对截至2025年12月31日合并报表范围内的各类资产计提了减值准备的会计 处理。 智通财经APP讯，华大智造(688114.SH)发布2025年年度业绩预告，经公司初步测算，预计2025年年度实 现归属于母公司所有者的净利润与上年同期(法定披露数据)相比，实现归属于母公司所有者的净利 润-27,300万元到-22,100万元，与上年同期相比，亏损将减少32,782.70万元到亏损减少37,982.70万元， 同比亏损减少54.56%到亏损减少63.22%。 ...

智通财经APP讯，华大智造(688114.SH)发布2025年年度业绩预告，经公司初步测算，预计2025年年度实 现归属于母公司所有者的净利润与上年同期(法定披露数据)相比，实现归属于母公司所有者的净利 润-27,300万元到-22,100万元，与上年同期相比，亏损将减少32,782.70万元到亏损减少37,982.70万元， 同比亏损减少54.56%到亏损减少63.22%。 报告期内，公司制定了一系列"提质增效重回报"措施，包括人效提升、研发聚焦、营销费用全周期管理 等措施，导致公司相关的成本费用相比同期减少。报告期内，由于美元、欧元汇率波动，导致公司持有 外币货币性项目产生的汇兑收益同比增加。报告期内，上半年对以前年度涉及的不确定性的税务争议风 险相应的税务拨备进行冲回处理，导致所得税费用同比减少。根据企业会计准则及公司会计政策等相关 规定，基于谨慎性原则，公司对截至2025年12月31日合并报表范围内的各类资产计提了减值准备的会计 处理。 ...

华大智造公告，预计2025年年度实现归属于母公司所有者的净利润与上年同期（法定披露数据）相比， 实现归属于母公司所有者的净利润-2.73亿元到-2.21亿元，与上年同期相比，亏损将减少3.28亿元到亏损 减少3.8亿元，同比亏损减少54.56%到亏损减少63.22%。 ...

Group 1 - The core viewpoint of the news highlights the strong performance of the pharmaceutical and medical services sectors, with the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index rising by 1.52% as of 11:05 AM on January 23, 2026, driven by significant gains in stocks such as Chengdu Xian Dao (+5.48%) and BGI Genomics (+4.25%) [1] - The Ministry of Commerce and eight other departments have issued opinions to promote high-quality development in the drug retail industry, encouraging retail enterprises to participate in centralized drug procurement and to enhance their bargaining power through joint purchasing [1] - The Chinese pharmaceutical industry is at a pivotal point for global value reassessment, with 2026 being a critical year to validate transformation outcomes, as highlighted by CITIC Securities [1] Group 2 - As of December 31, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index include companies like United Imaging Healthcare and BeiGene, collectively accounting for 48.85% of the index [2] - The CSI Innovation Medicine ETF closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index, providing an easy investment option for those without stock accounts through the linked fund [3]

Investment Rating - The report maintains an "Outperform" rating for several companies, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [6][7]. Core Insights - The annual J.P. Morgan Healthcare Conference concluded successfully, with positive information from global pharmaceutical companies, including new pipeline disclosures and major deals. The report highlights the high prosperity in the innovative drug sector and recommends continuous investment in innovative drugs and the industry chain [25][26]. - The A-Shares pharmaceutical sector underperformed the market in the third week of January 2026, with the Shanghai Composite Index falling by 0.4% and the SW Pharmaceutical and Biological sector declining by 0.7% [8][27]. - The Hong Kong stock pharmaceutical sector performed in line with the market, while the U.S. pharmaceutical sector underperformed. The Hang Seng Healthcare index increased by 2.4%, and the S&P 500 Healthcare Select Sector decreased by 1.1% [28]. Summary by Sections Section 1: Continuous Recommendation of Innovative Drugs and Industry Chain - The report emphasizes the high prosperity of innovative drugs and maintains overweight ratings for key pharmaceutical companies. It also recommends Biopharma/Biotech companies with promising pipelines and volume increases, as well as CXO and upstream companies benefiting from innovation [6][25]. Section 2: A-Shares Pharmaceutical Sector Performance - In the third week of January 2026, the A-Shares pharmaceutical sector's performance was ranked 17th among Shenwan primary industries, with a decline of 0.7%. The medical service sub-sector showed a positive performance of +3.3% [8][12][27]. Section 3: Hong Kong and U.S. Pharmaceutical Sector Performance - The Hong Kong pharmaceutical sector performed similarly to the market, while the U.S. sector underperformed. Notable gainers in the U.S. included MODERNA (+22%) and QUEST DIAGNOSTICS (+9%), while major decliners included BIOGEN (-12%) and BOSTON SCIENTIFIC (-10%) [28].

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4] Core Viewpoints - The US tumor gene testing industry is accelerating, and there are positive domestic opportunities. The market for gene testing has low penetration rates but high growth potential, particularly in colorectal cancer early screening, treatment selection, and minimal residual disease (MRD) testing, which are all billion-dollar markets [3][8] - The report emphasizes the importance of innovation in the pharmaceutical sector, highlighting that the Chinese pharmaceutical industry has completed a transition from old to new growth drivers, particularly in innovative drugs. Companies like Heng Rui Medicine and Han Sen Pharmaceutical have made significant strides in innovation [5][41] - The report suggests that the aging population and the increasing demand for healthcare services will continue to drive growth in the pharmaceutical industry, supported by a multi-layered payment system and advancements in technology such as AI and brain-computer interfaces [41][42] Summary by Sections Market Performance - From January 12 to January 16, the pharmaceutical index fell by 0.68%, with 202 stocks rising and 261 falling. The top gainers included Baolait (up 48.76%) and Hualan Biological (up 32.72%), while the biggest losers were Sunflower (down 37.48%) and *ST Changyao (down 33.33%) [5][25][27] Gene Testing Industry - The report highlights the rapid development of the US tumor gene testing industry, with companies like Natera and Guardant Health showing impressive revenue growth. Natera's Q4 2025 revenue reached $660 million, a 39% year-on-year increase, while Guardant Health's revenue for the same period was $280 million, also up 39% [8][9] - The report notes that the domestic gene testing market is expected to grow rapidly, with companies like BGI and Edan Diagnostics actively positioning themselves in the MRD and early screening sectors [24][22] Investment Recommendations - The report recommends focusing on strong fundamentals and undervalued stocks in the innovative drug sector, including companies like Xinyi Tai, Zecjin Pharmaceutical, and Shanghai Yizhong. It also suggests monitoring emerging technologies in healthcare, such as AI and brain-computer interfaces, which are expected to see significant advancements in 2026 [5][45][44] - Specific investment combinations for January include Xinyi Tai, China Biologic Products, and Sanofi Pharmaceutical, among others [45]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector [6][26]. Core Insights - The report emphasizes the continuous recommendation of innovative pharmaceuticals and medical devices, highlighting the high growth potential in the sector. It maintains "Overweight" ratings for companies such as Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also recommends Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][3]. Summary by Sections 1. Continuous Recommendation of Innovative Pharmaceuticals and Medical Devices - The report highlights the high growth potential of innovative drugs and recommends several companies for investment, including Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also suggests Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][7]. 2. A-share Pharmaceutical Sector Performance - In the third week of January 2026, the A-share pharmaceutical sector underperformed the broader market, with the Shanghai Composite Index declining by 0.4% and the SW Pharmaceutical and Biotech index falling by 0.7% [8][11]. 3. Hong Kong and US Market Performance - The Hong Kong pharmaceutical sector performed in line with the market, while the US pharmaceutical sector underperformed. In the same week, the Hang Seng Healthcare index rose by 2.4%, and the S&P 500 healthcare sector fell by 1.1% [19][20].

近10日内医疗健康R（480016）指数成份股做了调整，新纳入了1只股票，剔除了1只股票。 证券之星消息，1月16日，医疗健康R（480016）指数报收于7488.95点，跌0.88%，成交318.44亿元，换 手率1.07%。当日该指数成份股中，上涨的有13家，奕瑞科技以4.6%的涨幅领涨，下跌的有37家，华大 智造以6.61%的跌幅领跌。 医疗健康R（480016）指数十大成份股详情如下： 资金流向方面，医疗健康R（480016）指数成份股当日主力资金净流出合计3.81亿元，游资资金净流出 合计7.44亿元，散户资金净流入合计11.25亿元。成份股资金流向详情见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...